Resveratrol and its Nanoparticle suppress Doxorubicin/Docetaxel-resistant anaplastic Thyroid Cancer Cells in vitro and in vivo

Nanotheranostics

article

Le Xiong¹  Xiao-Min Lin¹  Jun-Hua Nie¹  Hai-Shan Ye¹  Jia Liu¹ 

[1] South China University of Technology School of Medicine;Guangzhou First People's Hospital, South China University of Technology ,(SCUT) School of Medicine

关键词: Resveratrol;    targeted nanoparticles;    anaplastic thyroid cancer;    docetaxel;    doxorubicin;    drug resistance;    tumor model;   

DOI  :  10.7150/ntno.53844

学科分类：大气科学

来源: Ivyspring International Publisher

【 摘 要 】

Background: Docetaxel and doxorubicin combination has been widely used in anaplastic thyroid cancer/ATC treatment but often results in serious adverse effects and drug resistance. Resveratrol effectively inhibits ATC cell proliferation in vitro without affecting the corresponding normal cells, while its in vivo anti-ATC effects especially on the ones with docetaxel/doxorubicin-resistance have not been reported due to its low bioavailability. Nanoparticles with sustained-release and cancer-targeting features may overcome this therapeutic bottleneck.

【 授权许可】

CC BY-NC